Trials / Completed
CompletedNCT03832114
Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted
An Open-label, Non-randomized Study on Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of LNP023 in Two Patient Populations With C3 Glomerulopathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is an open-label, two cohort non-randomized study evaluating the efficacy, safety, and pharmacokinetics of LNP023 in patients with C3G (Cohort A) and patients who have undergone kidney transplant and have C3G recurrence (Cohort B).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LNP023 | Increasing doses of LNP023 up to 200 mg. |
Timeline
- Start date
- 2019-02-20
- Primary completion
- 2021-04-23
- Completion
- 2021-04-23
- First posted
- 2019-02-06
- Last updated
- 2024-01-30
- Results posted
- 2022-07-08
Locations
9 sites across 6 countries: United States, France, Germany, Italy, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03832114. Inclusion in this directory is not an endorsement.